Taiwan
· Delayed Price · Currency is TWD Easywell Biomedicals Statistics
Total Valuation
Easywell Biomedicals has a market cap or net worth of TWD 13.95 billion. The enterprise value is 13.94 billion.
| Market Cap | 13.95B |
| Enterprise Value | 13.94B |
Important Dates
The next estimated earnings date is Tuesday, November 12, 2024.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Easywell Biomedicals has 121.87 million shares outstanding. The number of shares has increased by 2.15% in one year.
| Shares Outstanding | 121.87M |
| Shares Change (YoY) | +2.15% |
| Shares Change (QoQ) | +3.31% |
| Owned by Insiders (%) | 9.16% |
| Owned by Institutions (%) | 0.03% |
| Float | 54.82M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 37.00 |
| PB Ratio | 18.85 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -98.52 |
| EV / Sales | 38.55 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -63.22 |
Financial Position
The company has a current ratio of 4.02, with a Debt / Equity ratio of 0.55.
| Current Ratio | 4.02 |
| Quick Ratio | 2.89 |
| Debt / Equity | 0.55 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.86 |
| Interest Coverage | -7.85 |
Financial Efficiency
Return on equity (ROE) is -23.29% and return on invested capital (ROIC) is -8.84%.
| Return on Equity (ROE) | -23.29% |
| Return on Assets (ROA) | -7.79% |
| Return on Capital (ROIC) | -8.84% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.28 |
| Inventory Turnover | 1.48 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +426.20% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +426.20% |
| 50-Day Moving Average | 178.36 |
| 200-Day Moving Average | 102.04 |
| Relative Strength Index (RSI) | 32.50 |
| Average Volume (20 Days) | 854,618 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Easywell Biomedicals had revenue of TWD 361.49 million and -141.46 million in losses. Loss per share was -1.21.
| Revenue | 361.49M |
| Gross Profit | 230.14M |
| Operating Income | -158.59M |
| Pretax Income | -166.96M |
| Net Income | -141.46M |
| EBITDA | -114.08M |
| EBIT | -158.59M |
| Loss Per Share | -1.21 |
Balance Sheet
The company has 433.19 million in cash and 410.43 million in debt, giving a net cash position of 22.76 million or 0.19 per share.
| Cash & Cash Equivalents | 433.19M |
| Total Debt | 410.43M |
| Net Cash | 22.76M |
| Net Cash Per Share | 0.19 |
| Equity (Book Value) | 745.19M |
| Book Value Per Share | 6.07 |
| Working Capital | 508.35M |
Cash Flow
In the last 12 months, operating cash flow was -203.04 million and capital expenditures -17.39 million, giving a free cash flow of -220.43 million.
| Operating Cash Flow | -203.04M |
| Capital Expenditures | -17.39M |
| Free Cash Flow | -220.43M |
| FCF Per Share | -1.81 |
Margins
Gross margin is 63.66%, with operating and profit margins of -43.87% and -39.13%.
| Gross Margin | 63.66% |
| Operating Margin | -43.87% |
| Pretax Margin | -46.19% |
| Profit Margin | -39.13% |
| EBITDA Margin | -31.56% |
| EBIT Margin | -43.87% |
| FCF Margin | -60.98% |
Dividends & Yields
Easywell Biomedicals does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.15% |
| Shareholder Yield | -2.15% |
| Earnings Yield | -1.06% |
| FCF Yield | -1.58% |
Stock Splits
The last stock split was on September 30, 2022. It was a reverse split with a ratio of 0.7.
| Last Split Date | Sep 30, 2022 |
| Split Type | Reverse |
| Split Ratio | 0.7 |
Scores
Easywell Biomedicals has an Altman Z-Score of 4.9.
| Altman Z-Score | 4.9 |
| Piotroski F-Score | n/a |